English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 1 March 2019, 21:00 HKT/SGT

Source: NutraLife Biosciences, Inc.
NutraFuels, Inc. Explores New Delivery Systems with Pharmaceutical GMP Manufacturer

Coconut Creek, FL, Mar 1, 2019 - (ACN Newswire) - via NEWMEDIAWIRE -- NutraFuels, Inc (fka NutraLife Biosciences, Inc) plans to explore additional options for delivery systems for its nutraceutical and wellness products and pharmaceutical delivery systems.

"We are excited to be exploring our capabilities in the life sciences space by engaging in the research and development of more formulations and enhanced delivery systems with an experienced cGMP pharmaceutical manufacturer," said Edgar Ward, CEO and Founder of NutraFuels.

The Company plans to explore these various pharmaceutical formulations and delivery systems while utilizing the valuable experience of a cGMP pharmaceutical manufacturer.

NutraFuels manufactures and distributes private label and its own branded products under its NutraHempCBD and NutraSpray brands. The Company's product development, testing and research are conducted by four chemists under the supervision of Mr. Ward. The Company manufactures 100% of its products at its FDA registered facility in accordance with GMP standards.

NutraFuels, Inc (OTCQB: NTFU) is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (SEC). As filed with the SEC on November 13, 2018, the Company's financial results for the three (3) and nine (9) month period ended September 30, 2018 saw revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NutraFuels' filings with the SEC can be viewed at www.sec.gov, or on the Company website at www.NutraFuels.com.

NutraFuels' CBD products and information about the company's direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

NutraLife Biosciences, Inc
Coconut Creek, FL 33073
Telephone 1-888-509-8901

Forward-Looking Statements
This communication contains statements of a forward-looking nature about NutraFuels, Inc (the "Company"). These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. New risk factors emerge from time to time, and it is impossible for the Company's management to predict all risk factors, nor can the Company assess the impact of all factors on Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

Source: NutraFuels Inc.

Topic: Press release summary
Source: NutraLife Biosciences, Inc.

Sectors: Food & Beverage, BioTech, Healthcare & Pharm, Funds & Equities, Cosmetics, Spec.Chem
From the Asia Corporate News Network

Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


NutraLife Biosciences, Inc. Releated News
Apr 12, 2019 07:20 HKT/SGT
NutraLife Biosciences, Inc. enters Joint Venture with Henning Trading LLC to Cultivate and Process Hemp for 2019 U.S. Grow Season
Apr 4, 2019 05:00 HKT/SGT
NutraLife Bioscience, Inc. Reports 2018 Year End Financial Results
Mar 25, 2019 05:00 HKT/SGT
NutraLife Biosciences Encouraged By CVS Health Corporation's Decision to Distribute CBD at 800 Stores in the U.S.
Mar 15, 2019 05:00 HKT/SGT
NutraLife Bioscience, Inc. Receives License to Grow and Process Industrial Hemp
Mar 13, 2019 05:00 HKT/SGT
NutraLife Biosciences, Inc. Receives Contract to Provide Its Technologies and Delivery System for Pharmaceutical Products by cGMP Pharmacy
More news >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575